Therefore, we evaluated the expression levels of CXCL13, CXCR5 and CD8 in tissues by Immunohistochemistry (IHC) and Immunofluorescence (IF) to explore the prognostic value of the above pathological markers for NSCLC treated with ICIs. This evidence concerns the gene CXCR5 and non-small cell lung carcinoma.